In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Apomorphine Sublingual Film Filed in US: Sunovion
April 3, 2018
- Daiichi Sankyo Alters Terms of Settlement over US Olmesartan Products Liability Litigation
April 3, 2018
- Ambicion Obtains Global Rights to RIKEN’s NKT Cell-Targeted Anti-Cancer Therapy
April 3, 2018
- Shionogi Trio Puts Up Add’l 1.8 Billion Yen Each for Peptide Therapeutics JV
April 2, 2018
- Zeria Files Iron Deficiency Med in Japan
April 2, 2018
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Kihito Takahashi Tapped as EVP of GSK Japan
April 2, 2018
- Lynparza Companion Diagnostic Approved in Japan: AZ
April 2, 2018
- Keytruda Filed for Tumor-Agnostic Indication in Japan
April 2, 2018
- Generic Use Rate at 68.9% in October-December: JGA
April 2, 2018
- Bayer Gives Update on Initiatives after Xarelto Survey Scandal
March 30, 2018
- Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
March 30, 2018
- Fujifilm to Gobble Up 2 Cell Culture Media Firms for US$800 million
March 30, 2018
- Takeda Gets Japan Rights to Ammonul from Valeant
March 29, 2018
- Tokyo Court Strikes Down Baxalta Claim against Hemlibra: Chugai
March 29, 2018
- Janssen Files Japan NDA for Apalutamide in CRPC
March 29, 2018
- Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
March 29, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
- Sumitomo Dainippon to Transfer Back Office Staffers to Dedicated Subsidiary
March 28, 2018
- Tokyo Upstart Curadim In-Licenses Drug Candidate for IPF/NASH
March 28, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…